Home › Research › Prevention and risk
Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology
O'Brien JT, Holmes C, Jones M, Jones R, Livingston G, McKeith I, Mittler P, Passmore P et al.. Journal of psychopharmacology (Oxford, England), 2017-01-20
Topic: Risk, prevention and care in population studies
Though results of pivotal studies in early (prodromal/mild) Alzheimer's disease are awaited, results to date in more established (mild to moderate) Alzheimer's disease have been equivocal and no disease modifying agents are either licensed or can be currently recommended for clinical use.
Key findings
- Though results of pivotal studies in early (prodromal/mild) Alzheimer's disease are awaited, results to date in more established (mild to moderate) Alzheimer's disease have been equivocal and no disease modifying agents are either licensed or can be currently recommended for clinical use.
Why it matters
This consensus statement says that results in mild to moderate Alzheimer's disease have been equivocal and that no disease-modifying agents are licensed or can currently be recommended for clinical use. It states plainly that no such treatment is available, while results in early disease are still awaited.
New to this subject? Start with our plain-English guide: Prevention →
Study details
- Evidence strengthHigh
How this study scored 50/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on times cited, citations per year, impact for its field and year, cited by studies here and still being cited, so those were left out: it earned 36 of the 72 points we could judge it on, which is 50 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of psychopharmacology (Oxford, England)) |
| Journal's citation record | 2 / 4 | Journal of Psychopharmacology: journal h-index 168 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2017 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | Citation count not trusted: 3 of 9 library studies citing it were published more than a year before it - a sign OpenAlex merged several works under this DOI — left out of this score |
| Citations per year | — / 5 | Citation count not trusted (see above) — left out of this score |
| Impact for its field and year | — / 6 | Citation count not trusted (see above) — left out of this score |
| Cited by studies here | — / 6 | Library citations not trusted (see above) — left out of this score |
| Still being cited | — / 4 | Citation count not trusted (see above) — left out of this score |
| Senior author's track record | 3 / 4 | Last-listed author Alistair S. Burns: h-index 96 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University College London: institution h-index 2,029 (OpenAlex) |
| Multi-centre collaboration | 3 / 3 | OpenAlex lists 10 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 28103749) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 36 / 72 | Scored on 15 of 20 parts. We have no data for the rest, so they are left out: 36 of the 72 points we could judge it on is 50 out of 100. |
| Total | 50 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1177/0269881116680924
- PubMed: 28103749
- Original source →
- Free full text: ePrints Soton (University of Southampton) →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
APA 7th
O'Brien, J. T., Holmes, C., Jones, M., Jones, R., Livingston, G., McKeith, I., et al. (2017). Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology. Journal of psychopharmacology (Oxford, England). https://doi.org/10.1177/0269881116680924
Vancouver
O'Brien JT, Holmes C, Jones M, Jones R, Livingston G, McKeith I, et al. Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology. Journal of psychopharmacology (Oxford, England). 2017. doi:10.1177/0269881116680924. PMID: 28103749.
BibTeX
@article{obrien2017-28103749,
author = {O'Brien, J. T. and Holmes, C. and Jones, M. and Jones, R. and Livingston, G. and McKeith, I. and Mittler, P. and Passmore, P. and others},
title = {{Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology}},
journal = {Journal of psychopharmacology (Oxford, England)},
year = {2017},
doi = {10.1177/0269881116680924},
pmid = {28103749},
url = {https://doi.org/10.1177/0269881116680924}
}
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 82.
Later studies that cite this one
9 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Prevention and risk
Also tagged “prevalence”
1,224 studies in the library carry the topic tag “prevalence”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,224 tagged studies.